Method for Pathogen Identification

US 11,603,552 and US 11,851,698, assigned to Mesa Photonics LLC, cover method for determining enzymatic activity in a sample and a sample preparation protocol, and are available for sale through IPApproach.

US Patents

2 granted

Assignee

Mesa Photonics LLC

Availability

For Sale

Patents Included

• US 11,603,552↗
• US 11,851,698↗

Technology Highlights

• The invention is simple, easy to use, and does not require specialized personnel or complex equipment.
• The invention provides a scalable method that allows wide screening to prevent pathogen transmission and mitigate pathogen outbreaks.
• The invention provides a method for the identification of pathogens by monitoring the enzymatic cleavage rate of a substrate by the SARS-CoV-2 variant of the coronavirus enzyme.
• The invention offers a quick and efficient diagnostic assay that provides a positive or negative response within less than 15 minutes, with minimal interference from host enzymes.
• The invention delivers a diagnostic assay used to detect pathogens in humans, animals, and plants.
• The invention offers an activity-based diagnostic for a rapid response platform capable of detecting pathogens by measuring the activities of enzymes that are unique to a given pathogen.
• The invention provides the indication of the severity of the infection, since higher enzyme activity means a stronger infection.
• The invention reliably detects all pathogen variants, as mutations in enzyme active sites are incompatible with viral survival, making false negatives from variant mutations unlikely.
• The invention may directly measure the efficacy of natural, therapeutic, or vaccine-derived antibodies by detecting the activity of enzymes from pathogens that were able to enter a host cell.
• The invention may accelerate cell-based drug discovery by measuring the potencies of inhibitors against natural, unmodified enzymes.
• The invention provides semi-quantitative and/or quantitative detection of SARS PLpro activity in crude lysates collected from cells in the oral cavity.
• The invention offers a generic platform for detecting known and new variants that may evade detection by other methods such as RT-PCR and escape immunity from neutralizing antibodies.
• The invention provides a multiplex test to detect PLpro and ACE2 simultaneously.

Overview

The technology disclosed provides the following advantages:

Listing updated August 14, 2026

IPApproach lists patents and portfolios where the seller has not requested anonymity or confidentiality. Patent numbers link to public records on Google Patents.